Skip to main content

Lokelma Disease Interactions

There are 2 disease interactions with Lokelma (sodium zirconium cyclosilicate).

Major

Sodium zirconium cyclosilicate (applies to Lokelma) constipation/GI obstruction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of sodium zirconium cyclosilicate should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal postoperative bowel motility disorders. This medication has not been studied in patients with these conditions and may be ineffective and it may worsen gastrointestinal conditions.

References

  1. (2018) "Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals
Moderate

Sodium zirconium cyclosilicate (applies to Lokelma) edema

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Fluid Retention, Congestive Heart Failure, Renal Dysfunction

Each 5 g dose of sodium zirconium cyclosilicate contains approximately 400 mg of sodium, and can cause edema, which was generally mild to moderate in severity in clinical trials. Patients should be monitored for signs of edema, particularly those who should restrict their sodium intake or are prone to fluid overload (e.g., heart failure or renal disease). Advise patients to adjust dietary sodium, and if appropriate, increase the dose of diuretics as needed.

References

  1. (2018) "Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals

Lokelma drug interactions

There are 18 drug interactions with Lokelma (sodium zirconium cyclosilicate).

Lokelma alcohol/food interactions

There is 1 alcohol/food interaction with Lokelma (sodium zirconium cyclosilicate).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer